Genito-Urinary Syndrome of Menopause (GSM) is a chronic condition that typically arises in women five to six years after menopause. The term was formally introduced in 2014 to describe a cluster of symptoms affecting the bladder, vagina, and urethra. While symptoms often manifest later, they can appear earlier due to estrogen deficiency. Early menopause may result from primary ovarian insufficiency, postsurgical menopause, or cancer treatments.

During menopause, the ovaries produce significantly less estrogen. This hormonal shift can cause the vaginal tissues to become thinner, drier, more fragile, and prone to soreness. The bladder may also become hypersensitive, leading to urinary leaks or recurrent infections. However, estrogen levels can drop well before natural menopause due to several factors, including:

• Breast or pelvic cancer treatments
• Surgical removal of both ovaries
• Certain medications
• Breastfeeding

Figure 1: Hormonal changes and their impact on pelvic health during menopause

How Do Doctors Diagnose GSM?

There is no specific blood test or imaging scan for GSM. Diagnosis is primarily clinical, based on a thorough symptom history and a pelvic examination. Healthcare providers assess for signs of tissue thinning, inflammation, and structural changes in the vagina, vestibule, and urethra, while also ruling out infections or other conditions.

The most common clinical presentations include:

• Vaginal dryness or soreness
• Pain during sexual intercourse (dyspareunia)
• Itching, burning, or a sensation of tightness in the vagina
• Light bleeding after intercourse
• Burning or pain during urination
• Frequent or urgent need to urinate
• Urinary incontinence (leaking)
• Recurrent urinary tract infections (UTIs)
• Pathological vaginal discharge due to altered vaginal flora
• Increased susceptibility to opportunistic infections, such as fungal infections

Figure 2: Clinical evaluation and pelvic examination for accurate GSM diagnosis

Bridging the Awareness & Treatment Gap

Unfortunately, a significant gap exists between symptom onset and treatment-seeking behavior. This is largely driven by limited access to specialized services and a lack of public awareness. There is an urgent need for targeted educational campaigns. Healthcare providers, in particular, must be equipped with up-to-date knowledge to counsel and support affected women. Routine screening for GSM symptoms during standard gynecological examinations could dramatically improve early diagnosis rates.

Modern Management Strategies

Treatment approaches for GSM have evolved considerably, with both hormonal and non-hormonal therapies demonstrating proven efficacy:

• Local Vaginal Estrogen Therapy: Recognized as the gold standard for moderate to severe cases, it offers targeted relief with minimal systemic absorption.
• Non-Hormonal Options: Vaginal moisturizers and lubricants are highly beneficial for mild symptoms or for women with contraindications to estrogen.
• Emerging Therapies: Selective estrogen receptor modulators (SERMs) and vaginal laser treatments show promise, though their long-term safety profiles and cost-effectiveness require further clinical validation.

Figure 3: Comprehensive treatment approaches improving quality of life for women with GSM

Impact on Quality of Life & A Holistic Approach

GSM profoundly impacts a woman’s quality of life, particularly her sexual health and interpersonal relationships. Dyspareunia and reduced lubrication frequently lead to decreased sexual satisfaction and avoidance of intimacy, which can trigger psychological distress and relational strain. Addressing GSM effectively requires a comprehensive, patient-centered approach that integrates education, counseling, and individualized treatment planning.